The April 2023 catch-up price reductions are causing significant concern across the biopharmaceutical sector and while the framework has captured many recently reimbursed brands it has the appearance of targeting one particular group of medicines. …
The appearance of a pricing policy targeting one group of medicines
August 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
New report highlights widening gap in access to modern medicines between Australia and NZ
October 8, 2025 - - Latest News -
RACGP warns of mounting pressure on GPs as costs and complexity rise
October 7, 2025 - - Other Health -
AusBiotech’s annual report highlights a defining year for Australia’s life sciences sector
October 7, 2025 - - Australian Biotech -
AstraZeneca becomes the latest to say it could halt UK investment over 'appalling' pricing regime
October 7, 2025 - - Latest News -
MTPConnect and Wholesale Investor unite to accelerate investment in life sciences sector
October 7, 2025 - - Australian Biotech -
Percheron Therapeutics reports positive final data from early-phase trial of HMBD-002
October 7, 2025 - - Australian Biotech -
FDA clears clinical hold on Neurizon's NUZ-001, paving way for HEALEY ALS trial
October 7, 2025 - - Australian Biotech